Ebos's 1H Result Probably Enough to Rebuild Investor Confidence -- Market Talk

Dow Jones

02/26

0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. "Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix," analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

February 25, 2026 21:26 ET (02:26 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614064103"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614064103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614064103?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614064103","market":"sh","top_or_hot":-1,"title":"Ebos's 1H Result Probably Enough to Rebuild Investor Confidence -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. \"Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix,\" analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 21:26 ET (02:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ebos's 1H Result Probably Enough to Rebuild Investor Confidence -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEbos's 1H Result Probably Enough to Rebuild Investor Confidence -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-26 10:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. \"Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix,\" analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 21:26 ET (02:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK8046","symbol_name":"保健護理產品經銷商","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614064103","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614064103","pubTimestamp":1772072760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. \"Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix,\" analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK8046":"保健护理产品经销商","EBO.NZ":"Ebos Group Limited Ordinary Shares","BK7103":"保健护理产品经销商","EBO.AU":"EBOS GROUP LIMITED"},"translate_title":"Ebos上半年业绩可能足以重建投资者信心——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBO.NZ":0.9,"EBO.AU":0.9},"content_text":"0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. \"Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix,\" analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 21:26 ET (02:26 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}